Articular Cartilage Defect - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Articular Cartilage Defect - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Articular Cartilage Defect - Pipeline Review, H2 2014', provides an overview of the Articular Cartilage Defect's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Articular Cartilage Defect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Articular Cartilage Defect and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Articular Cartilage Defect
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Articular Cartilage Defect and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Articular Cartilage Defect products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Articular Cartilage Defect pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Articular Cartilage Defect
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Articular Cartilage Defect pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Articular Cartilage Defect Overview 6
Therapeutics Development 7
Pipeline Products for Articular Cartilage Defect - Overview 7
Pipeline Products for Articular Cartilage Defect - Comparative Analysis 8
Articular Cartilage Defect - Therapeutics under Development by Companies 9
Articular Cartilage Defect - Therapeutics under Investigation by Universities/Institutes 10
Articular Cartilage Defect - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Articular Cartilage Defect - Products under Development by Companies 14
Articular Cartilage Defect - Products under Investigation by Universities/Institutes 15
Articular Cartilage Defect - Companies Involved in Therapeutics Development 16
Cellular Biomedicine Group, Inc. 16
MediPost Co., Ltd. 17
Vericel Corporation 18
Articular Cartilage Defect - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 21
Drug Profiles 23
human umbilical cord blood-derived mesenchymal stem cells - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
matrix-applied characterised autologous cultured chondrocytes - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ReJoin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Stem Cell Therapy for Cerebral Hemorrhage and Articular Cartilage Defect - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Stem Cell Therapy for Osteoarthritis and Articular Cartilage Defect - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Articular Cartilage Defect - Recent Pipeline Updates 29
Articular Cartilage Defect - Dormant Projects 33
Articular Cartilage Defect - Product Development Milestones 34
Featured News & Press Releases 34
Sep 16, 2014: Aastrom Biosciences to Present Three-Year Data From the SUMMIT Extension Study of MACI at the 2015 American Academy of Orthopedic Surgeons Annual Meeting 34
Apr 26, 2013: Genzyme Receives CHMP Recommendation For Approval Of MACI For Treatment Of Articular Cartilage Defect 34
Oct 30, 2012: Duke Researchers Engineer Cartilage From Pluripotent Stem Cells 35
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Number of Products under Development for Articular Cartilage Defect, H2 2014 7
Number of Products under Development for Articular Cartilage Defect - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Articular Cartilage Defect - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 16
Articular Cartilage Defect - Pipeline by MediPost Co., Ltd., H2 2014 17
Articular Cartilage Defect - Pipeline by Vericel Corporation, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Route of Administration, H2 2014 20
Number of Products by Stage and Molecule Type, H2 2014 22
Articular Cartilage Defect Therapeutics - Recent Pipeline Updates, H2 2014 29
Articular Cartilage Defect - Dormant Projects, H2 2014 33